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Abstract 
 
Introduction: Alzheimer’s disease (AD) is a neurodegenerative condition that is 
becoming a global crisis with no current cure. Neuroinflammation is widely 
thought to play a role in the pathogenesis of this disorder. Peripheral levels of the 
cytokine interleukin 6 (IL-6), that has both pro- and anti-inflammatory properties 
have been linked to dementia and age-related cognitive decline. Polymorphisms 
in the IL-6 gene have also been associated with neurodegenerative diseases. 
However, it remains to be determined how IL-6 levels are regulated in AD within 
brains and how this relates to neuropathology. 
Aim: The aim of this project was to investigate if and how the IL-6 gene is 
regulated in the brain during cognitive decline and AD and its relationship to 
neuropathological markers of AD. 
Methods: This study investigated IL-6 within brains from the University of 
Manchester Age and Cognitive performance research Cohort (ACPRC) and the 
Dyne – Steele study, that have been longitudinally followed over a 20-year period 
for cognition and characterised in neuropathology stages. Genotyping for the 
single nucleotide polymorphism (SNP) rs1800795 in the IL-6 locus was performed 
using KASP and IL-6 gene expression was measured by RT-PCR and normalised 
using two housekeeping genes (βactin and GAPDH). ELISA was used to determine 
IL-6 protein levels in brains and bisulphite pyrosequencing was used to quantify 
methylation levels of CpG sites at the IL-6 promoter. Finally, immunofluorescence 
was used to compare control and early AD prefrontal cortex brain samples to 
enable investigation of the distribution of IL-6 and an important regulator, NFkB. 
Results: Between genotypes, no significant difference was observed in age of 
death, whole brain weight, post mortem delays and neuropathology stages. IL-6 
protein levels were analysed at the different neuropathology stages (BRAAK, THAL 
and CERAD) with no significance determined between each of the stages in the 
neuropathological hallmarks. Levels of IL-6 protein and IL-6 mRNA expression 
were analysed between the different genotypes with no significant differences. IL-
6 gene expression and IL-6 total protein levels showed no correlations, even when 
further stratified by genotype. Immunofluorescence determined that IL-6 is 
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present in the prefrontal cortex of both control and early AD samples and NFkB is 
activated. Distribution of DNA methylation at 4 CpG sites in the IL-6 promoter 
were determined. CpG site 2 depends on the rs1800795 SNP, which is only 
present in the G allele carriers. Interestingly, in the G allele carriers, levels of 
methylation at CpG sites 3 and 4 were significantly lower and higher, respectively. 
Levels of DNA methylation between control and AD groups were not significantly 
different at each of the CpG sites and did not correlate with protein levels. Levels 
of IL-6 mRNA and DNA methylation stratified by genotype revealed no correlation. 
Discussion: This study is the first to investigate IL-6 in AD brains and mechanisms 
underlying its epigenetic and genetic regulation. IL-6 protein levels and mRNA 
levels are found not to be impacted by the genotype and in disease state. 
Interestingly, DNA methylation was shown to be altered in the brains by the 
presence of a SNP, suggesting gene-environment interactions however, this was 
not influenced by disease state. In summary, the research has shown that IL-6 is 
present in control and AD brains and that the SNP has an impact on methylation 
levels between genotype at different CpG sites. However direct linear correlations 
between methylation, protein and expression levels did not exist. IL-6 is an 
important mediator of inflammation and further work is needed to understand 
how this factor is involved in neuroinflammation and regulated in the 
pathogenesis of AD. 
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1.0 Introduction 
 
1.1 Epidemiology of Dementia 
Dementia has many forms and the most prevalent form of the disease is 
Alzheimer’s disease (AD) corresponding close to 60% of cases (Rizzi et al., 2014). 
The analysis of AD brains at post-mortem has led to evidence suggesting the 
involvement of inflammation in the pathology (Zheng et al., 2016). AD is a 
neurodegenerative condition, which is progressive over time and results in 
cognitive decline. Molecular features of AD are beta-amyloid plaques (Aβ) and 
neurofibrillary tangles (NFT) composed of tau proteins (Jones et al., 2017). There 
is currently a global crisis surrounding dementia as currently over 40 million 
people suffer with the disease worldwide (Zheng et al., 2016) and that is set to 
triple by the year 2050 to 115 million people as life expectancy increases (Liu and 
Chan, 2014). Women have a higher chance of developing dementia compared to 
men (Alzheimers, 2015). 
 
1.2 Clinical symptoms of MCI and AD 
Mild cognitive impairment is categorised based on thinking skills and memory 
impairment. An example could be that a person starts to forget important 
information such as appointments or recent events as well as lacking the ability to 
make sound decisions (Langa and Levine, 2014). Signs and symptoms of AD can 
vary depending on the person affected. During the early stages of AD, it is 
possible for the person to be independent and carry on with day-to-day life. Over 
time during this stage, it may become noticeable that a person is struggling more 
to find the correct words or even struggling to remember information they have 
just read. Eventually, the condition will develop into the moderate AD stage. Once 
the disease has progressed to this stage, a greater level of care is needed due to 
the patient becoming less independent in day-to-day life. This stage is usually the 
longest stage and can last several years. Symptoms become more heightened and 
more notable. Such symptoms can include forgetfulness and becoming 
increasingly withdrawn from society, family and friends. The last stage of AD is 
reached when individuals lose the ability to respond to their environment. 
14 
 
Conversation abilities and controlling movements will become progressively more 
difficult. As memory and cognitive skills continue to decline, changes in 
personality may take place. During the last stages of the disease, special care 24 
hours a day will be needed. There will be difficulty with physical abilities such as 
being able to sit or even walk. Due to the deterioration on the individual and their 
body, they become increasingly open to developing infections such as pneumonia 
which can be life threatening. Eventually death will occur, as there is no cure for 
the illness (Alzheimers, 2015). 
1.3 Diagnosis of dementia with specific relation to AD 
Diagnosis of AD is not definitive until death and a postmortem is completed. 
During autopsy, the brain may be examined for amyloid plaques and tau proteins 
which are the classic hallmarks of AD (Kumar and Clark, 2017). However, if some 
form of dementia is suspected a doctor can carry out a number of tests to aid in 
trying to diagnose the condition (Neugroschl and Wang, 2011). Recently there 
have been developments in clinical diagnostic techniques for AD. Blood tests are 
carried out which would include looking at full blood count, B12, thyroid function, 
urea, liver function test and glucose levels. Brain imaging can be used for the 
investigation of AD. Magnetic resonance imaging (MRI) is a useful imaging tool to 
look at patterns of regional brain atrophy (Kumar and Clark, 2017). More recently, 
positron emission tomography (PET) is used to indicate characteristic changes in 
AD brains. Imaging has a key role in the diagnosis of AD, as the brain cannot be 
assessed until death to perform histopathology for confirmation of AD. 
Furthermore, imaging is a tool that could have significance in diagnosing AD 
through diagnostic markers (Johnson et al., 2012). Clinicians often use the mini 
mental state examination (MMSE) to aid in diagnosing AD and to monitor the 
progression and severity. This test consists of a scoring system with the score 
being out of 30. Individuals who score 27 or over are considered as normal. A 
MMSE score of 20-26 can indicate mild AD in patients. A score between 10 and 20 
suggests moderate AD and below 10 would be considered as having severe AD 
(Kukull et al., 1994). This tool is helping to diagnose AD, however a level of 
professional judgement is needed as the results can be affected by the cultural 
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background or level of education of the patient. The neuropathological diagnosis 
of AD involves looking at 3 different neuropathological staging and they are THAL, 
CERAD and BRAAK. Description of the 3 different staging can be seen below in 
table 1  
Table 1 - Description of neuropathological staging and brain regions affected 
THAL  
Staging 
(Serrano-
Pozo et al., 
2011) 
Assess amyloid 
deposition 
 
Stage 1 Amyloid deposits found in the isocortical region 
Stage 2 Amyloid deposits present in the hippocampal, 
entorinal cortex, insular and cingulated cortices 
Stage 3 Amyloid deposits present in the thalamus, 
hypothalamus, white matter and basal forebrain 
cholinergic nuclei 
Stage 4 Amyloid deposits present in the brainstem 
structures. e.g. substantia nigra, reticular 
formation of the medulla oblongata 
Stage 5 Amyloid deposits present in the pons and the 
molecular layer of the cerebellum 
BRAAK 
Staging 
(Braak et 
al., 2006) 
(Murayama 
and Saito, 
2004) 
Assess 
neurofibrillary 
tangles 
 
Stage I-II Classified when neurofibrillary tangles are 
confined in the transentorhinal region and 
entorhinal region  
Stage III-IV Classified when the NFT are involved in 
the limbicregions. An example of this is in the 
hippocampus. (Murayama and Saito, 2004) 
Stage V-VI Significant neocortical involvement, isocortical 
involvement and substantia nigra. (Murayama 
and Saito, 2004) 
CREAD 
Stages 
(Fillenbaum 
et al., 2008) 
(Murayama 
and Saito, 
2004) 
Assess neuritic 
plaques 
 
0 - None No histological evidence of AD. 
1 - Sparse Sparse formation of neuritic plaques. Uncertain 
evidence of AD 
2 - 
Moderate 
Moderate formation of neuritic. Suggested 
diagnosis of AD 
3 - 
Frequent 
Frequent formation of neuritic. Indicate 
diagnosis of AD 
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1.4 Risk factors associated with dementia (specifically AD) 
There are numerus risk factors that are linked with AD, including lifestyle, vascular 
and genetic factors (Bekris et al., 2010). The chance of developing dementia varies 
from person to person. Age is one of the main risk factors for developing 
dementia. According to Alzheimer’s society website, 6 out of a 100 people aged 
75-79 will have dementia. This increases with age and 30 out of a 100 people 
aged 90-94 will suffer from dementia (Alzheimer society, 2018). Making certain 
changes to the lifestyle can increase or decrease the chances of developing 
dementia. Maintaining a lifestyle that is healthy could potentially help protect 
against developing dementia such as regular exercise and mental stimulation 
(Alzheimers, 2015). Obesity affects many different organ systems and this 
disease is very damaging. Obesity is associated with higher risk of developing 
mild cognitive impairment (MCI) and late-life dementia and AD (Nguyen et al., 
2014). Recently a number of studies have linked traumatic brain injury (TBI) as a 
risk factor in developing AD. Results have shown that after TBI, microglia can 
remain activated months to several years. This is significant as after the injury this 
function is necessary for phagocytic clearance of debris. The constant cerebral 
inflammation that occur from this process could intern directly or indirectly cause 
AD (Donat et al., 2017). There is also a genetic risk that can be associated with 
dementia which is caused by autosomal dominant mutations. There are a 
number of genes that can be affected, and these include Aβ precursor protein 
(APP), presenilin 1 (PSEN1) and 2 (PSEN2), which are linked to AD. There are 3 
different alleles associated with ApoE gene which include ε2, ε3 and ε4 of which 
ε4 is seen to increase AD risk in familial and sporadic cases (Liu et al., 2013). It is 
important to note that just because there is an inheritance of the ε4 allele it does 
not guarantee the development of AD. In the brain, the APOE protein binds to Aβ 
strongly and is present in the plaques found in AD (Jungsu et al., 2009). Genetic 
factors have been seen to play an important role in AD. Genetic variants in the 
genome have been analysed through genetic wide association studies (GWAS). A 
common strategy to assess genetic variants in the genome is through GWAS to 
observe single nucleotide polymorphism (SNP) arrays to assess the association 
with AD. Single nucleotide polymorphism of interest during this project is 
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rs1800795, which resides at -147 base pair upstream from the IL-6 (Zhang et al., 
2015). 
 
1.5 Neuroinflammation in the brain and in relation to AD 
When damage occurs to the human body for example physical injury then 
inflammation is the response (Weiss, 2008). This inflammatory response is the 
body’s way of controlling and maintaining its homeostasis (Kunnumakkara et al., 
2018). There are two types of inflammatory responses and they are acute and 
chronic inflammation. Acute inflammation usually occurs when the healing 
process begins and starts to repair the damaged tissues. Whereas chronic 
inflammation, persists in trying to repair tissue but also damages tissues at the 
same time (Weiss, 2008). Risk factors that are associated with chronic 
inflammation include age, obesity, diet, smoking, sleep and stress. Features of 
chronic inflammation include vasodilation of the blood vessels, blood flow 
increases and neutrophils move towards the affected area. The continued 
inflammation presence in the human body can lead to various diseases. Examples 
can include cancer, arthritis, diabetes and neurological disease. This is through the 
dysregulation of signalling pathways such as NFκB. This is of importance as 
targeting the signalling pathways potentially has the effect to eradicate many 
diseases. There are numerus transcription factors that have been discovered to be 
linked to inflammation. Some examples of cytokines that are involved include 
tumor necrosis factor alpha (TNF-α) and interleukins (IL) such as IL-1 and 6. NFκB 
is an important transcription factor as it is seen to be the key mediator in 
inflammation. (Kunnumakkara et al., 2018). Neuroinflammation over the past 10 
years has developed into a concept that is accepted. However, it is still not 
presently clear what mechanisms are involved. Neuroinflammation has a role in 
neurodegenerative diseases (Calsolaro and Edison, 2016).The pathophysiology of 
neuroinflammation is extremely complex and many different brain cells can drive 
the activation (Bronzuoli et al., 2016). Neuroinflammation is when there is 
activation of microglia, astrocytes, macrophages and lymphocytes that result in 
the release of inflammatory mediators such as cytokines and chemokines (Lee et 
al., 2010). 
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1.6 The role of IL-6 in relation to neuroinflammation, MCI and AD 
Interleukin 6 (IL- 6) was discovered 30 years ago (María Erta, 2012)and is a 
proinflammatory cytokine with multiple functions and has neuro-protective 
properties, but also has degenerative properties (Baune et al., 2012). The 
molecular weight of IL-6 is 20-30kD. The main source of IL-6 include cells in the 
immune system and adipocytes. NFkB moderates expression of IL-6 and the 
protein is upheld in the cytoplasm by the binding of inhibitory proteins (Maggio et 
al., 2006). IL-6 is shown to be key in chronic inflammation, and levels are elevated 
in inflammatory diseases (Gabay, 2006). When inflammation occurs which can be 
acute or chronic, IL-6 proteins are produced at the inflammation site. Microglia 
and astrocytes are stimulated by the accumulation of Aβ plaques and tau 
proteins, this leads to the increased production of inflammatory mediators like IL-
6 (María Erta, 2012). Many different types of cytokines are secreted by microglia 
and have been seen to have altered expression in AD patients. As well as several 
polymorphisms of pro-inflammatory genes are seen to be related to increased risk 
of AD (Solito and Sastre, 2012). In AD brains, IL-6 accumulates around amyloid 
plaques as well as other cytokines. This has led to studies looking at pro-
inflammatory and anti-inflammatory cytokine levels in cerebral spinal fluid (CSF) 
and blood serum in patients with AD and MCI (Zheng et al., 2016). Cojocaru et 
al.(2011) compared IL-6 levels between control and AD patients to determine the 
correlation of IL-6 levels in the disease pathology of AD. It was discovered that 
levels of IL-6 were significantly higher in AD patients when compared to the 
control group. Indicating an increase in production of IL-6 cytokine in AD patients. 
 
1.7 Epigenetic and DNA methylation 
Epigenetics is the changes in gene expression which don’t change DNA sequence 
itself. Epigenetic modifications can be altered through life-time and affected by 
the environment, e.g. in response to nutrients, stress, infections, and toxin 
exposure (Bayarsaihan, 2016). Epigenetic mechanisms include DNA methylation, 
changes in histone marking and microRNAs. DNA methylation is one of the most 
widely studied epigenetic markers. It involves the addition of methyl groups to 
cytosine residues, usually in a CG sequence, termed CpG. Such methylated CpGs 
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within promoter regions of genes generally have a repressing activity on gene 
expression either by blocking transcriptional activators from binding or recruiting 
repressive histone markers. Patterns of DNA methylation are regulated through 
the activity of DNA methyltransferases and demethylation enzymes (Moore et al., 
2013). Hypermethylation in the promoter region of genes can be associated with 
transcriptional silencing while hypomethylation induces gene expression (Yasmin 
et al., 2015). The brain contains some of the highest levels of DNA methylation 
compared to any other tissue. The epigenetic regulation of genes within the brain 
is important for neurodevelopment and brain function. Numerous studies have 
linked changes in the patterns of DNA methylation within the brain to 
neurological diseases. There is increasing evidence that neurons respond to 
environmental signals via changes in DNA methylation (Murgatroyd et al., 2009). 
Epigenetic mechanism mediates the development of chronic inflammation by 
modulating the expression of pro – inflammatory cytokines such as interleukin’s, 
TNFα and oncogenes of the transcription of NFκB. These molecules are produced 
by many different cells during chronic inflammation. This can lead to the 
development of some very serious conditions such as autoimmune disorders, 
cancers and neurodegenerative conditions (Shanmugam and Sethi, 2013). The 
inflammatory genes are regulated through DNA methylation, histone modification 
and transcription factors such as NFκB, FOXP3 and STAT (Bayarsaihan, 2016). DNA 
methylation levels have been indicated in other genes such as BDNF and OPRK1 
promoters in AD patients (Ji et al., 2017). The status of methylation is particularly 
analysed in the promoter regions of genes, which are linked to AD pathology 
(Chouliaras et al., 2010a). Promoter methylation is important in the epigenetic 
mechanism of the regulation of the expression of IL-6 (Coppieters and Dragunow, 
2011). Changes through environmental and functional genes could change 
hypermethylation and hypomethylation at sites which implicated gene expression 
(Levine et al., 2015). It is known that the epigenetic process of DNA methylation 
influences numerous genes that are involved in inflammation. In a recent study 
Nicolia et al. (2017) focused on late onset AD and neuroinflammation to analyse 
the possible association with epigenetic modification. Analysis was conducted on 
human brain tissues from the frontal cortex of healthy middle aged and late onset 
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AD at different BRAAK stages. In the control group mRNA IL-6 methylation is seen 
to decrease as DNA methylation increases. The opposite is noted at BRAAK stages 
I-II/A, mRNA IL-6 levels increase as DNA methylation decreases. Whereas at AD 
BRAAK grouping V-VI/C both IL-6 mRNA levels and DNA methylation decrease.  
This could be indicating that no relation is present with methylation levels and 
mRNA expression. Another observation presented was, in the 5-flanking region of 
the IL-6 gene high levels of methylation were observed in middle age cases with 
progressive hypomethylation at stages I-II/A and stages V-VI/C. This is important 
as hypomethylation is seen to be an epigenetic abnormality. For example 
hypomethylation is linked to increased inflammatory mediators which could be 
linked to neuroinflammation and AD. Concluding remarks from this paper is that 
there is a need to study whole methylation site in DNA promoters and flanking 
regions, this is to show that expression of cytokines genes is linked with 
differential DNA methylation in brains from late onset AD patients. 
 
1.8 Regulatory polymorphisms in IL-6 
In excess of 3.1 million SNPs are found in the genome of humans if not more. 
Mental health and its association with polymorphisms has been investigated but 
there are recently inconsistences between research. Many polymorphisms have 
the potential to be regulatory. These can be positioned in promoter regions 
upstream, downstream and in introns. In recent years, the significant 
development in sequencing has allowed human genome analyses to become 
cheap and fast. The understanding of the human genome is ever changing and 
evolving (Paul, 2011). One particular single nucleotide polymorphism is rs1800795 
which is found in the promoter region of the IL-6 gene (Dragašević et al., 2014). 
The IL-6 gene is found on the short arm of chromosome 7 (7p21) (Baune et al., 
2012) and IL-6 is made of 212 amino acids (Tanaka et al., 2014). This SNP is linked 
to transcription rates and is linked to various diseases such as diabetes and AD. 
The IL-6 gene promoter includes numerous regulatory sites to enable the control 
of gene expression (Popko et al., 2010), such as NFκB, C/EBP, CREB and AP1 as 
well as numerous other transcriptional factors regulate IL-6 mRNA expression 
(Wongchana and Palaga, 2012). The C allele in the polymorphism has been seen 
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to have lower IL-6 gene expression and IL-6 plasma levels (Capurso et al., 2004). 
Licastro et al. (2003) reported that in the IL-6 promoter region the rs1800795 (-
174) allele was over represented in AD compared to the control group and seen 
to increase the risk of AD. IL-6 polymorphism rs1800795 is located in the 
promoter region residing at -174 base pair upstream. This polymorphism can 
affect the transcription of the gene and could alter cytokine production (Liu et al., 
2017), suggesting it has an effect upon IL-6 gene expression and protein levels. 
The rs1800795 (G) allele has been studied in a number of different conditions and 
has been found to have higher levels of IL-6. The rs1800795 (C) allele has also 
been studied in many different conditions and has been associated with lower 
levels of IL-6 (SNPedia). Noss et al (2015) found an association between the 
rs1800795 minor allele (C) and the association between increased IL-6 
productions in fibroblasts. On the other hand, in human monocytes and HeLa cell 
no association was found between increased IL-6 production and the rs1800795 
polymorphism. 
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2.0 Aims and Objectives 
 
2.1 Aims 
 
To determine epigenetic mechanisms by which the IL-6 gene is regulated in the 
brain in neuroinflammation, cognitive decline and AD. 
 
2.2 Objectives 
 
The molecular mechanisms underlying IL-6 regulation in the brain were 
addressed. A collection of brains assessed longitudinally for cognitive decline 
(prefrontal cortex, n=67) was measured for protein levels of IL-6 using enzyme-
linked immunosorbent assay (ELISA) to test relationship of IL-6 levels in cognitive 
decline and AD. 
 
Levels of DNA methylation at the IL-6 promoter were determined, using bisulfite 
pyrosequencing. Gene expression of IL-6 were measured by RT-PCR and 
genotyping using Kompetitive allele-specific PCR. Finally, the role of genetics and 
gene-environment interactions in the regulation of IL-6, a polymorphism in the 
gene was correlated with IL-6 brain expression and DNA methylation. This allowed 
the determination of whether interactive effects of gene-epigenetic factors could 
work at the IL-6 gene. 
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3.0 Methodology 
 
3.1 Reagents and supplies 
All reagents, kits, chemicals and other laboratory equipment used in this project 
can be found in Appendix 10.1. 
 
3.2 Study population 
This project investigated n=67 prefrontal cortex samples acquired from the 
Manchester Brain Bank (with full ethical approval for all experiments described in 
section 3). The individual brain samples were from a larger cohort called The 
University of Manchester Age and Cognitive performance Research Cohort 
(ACPRC). The pre frontal cortex samples were stored in the -80⁰C freezer. As seen 
below in table 2, some of the sample data is missing, which is indicated by the 
sample size. 
Table 2 - Table of characteristics from participants for prefrontal cortex analysis.  
 
 
 
 
 
 
A n=43. B n=60. All data presented as mean (standard deviation), unless stated 
otherwise. 
 
 
 
 
 
Variable n=67 
Age of death 87.51 ± (6.07) 
Brain weight (g)A 1207.37± (137.37) 
Post-mortem delay 
(hours)B 
76.14 ± (43.68) 
Age at cognitive testing 62.85 ± (5.84) 
Females/Males (%) 46 (68.7) / 24 (31.3) 
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3.3 DNA extraction 
Frozen prefrontal cortex samples were subjected to DNA extraction using the 
isolate II genomic DNA kit (Bioline) with a few alterations through previous 
optimisation. Prefrontal cortex brain samples were placed on dry ice during the 
cutting stage to stop thawing of the tissues. Brain tissues were weighed in the 
region of 35 mg, placed in individual eppendorf tubes, and labelled. In each of the 
tubes 250 μl of lysis buffer and 30 μl proteinase K solution was added and mashed 
until the samples could pass through the pipette tip. Samples were incubated 
overnight at 56 oC on a heat block with a shaking option set to 1200 rpm. After the 
incubation period, the samples were vortexed and 200 μl of lysis buffer G3 was 
loaded into each eppendorf, vortexed and incubated for a further 10 minutes at 
70oC.  In each tube 210 μl of ethanol (96-100%) was added and vortexed 
vigorously. Samples were then loaded into isolate II genomic DNA spin columns 
and centrifuged at 11000 x g for 1 minute. To each of the spin columns 500 μl of 
GW2 wash buffer was added and centrifuged at 11000 x g with flow through 
discarded. GW2 wash buffer is added for a second time (600 μl) to each spin 
column and centrifuged at 11000 x g discarding the flow through. Spin columns 
were centrifuged again and placed in new collection tubes to elute the DNA in 45 
μl of elution buffer G at 70OC with an incubation period of 1 minute at room 
temperature. Spin columns were centrifuged and extracted DNA was collected 
and purity measured using the Nanodrop 2000c. Purity levels for A260/280 were 
2.02 ± 0.08 and A230/260 purity level were 2.22 ± 0.16 indicating DNA purity 
levels were acceptable. 
 
 
 
 
 
 
 
25 
 
3.4 Bisulphite conversion 
The DNA extracted from the n=67 prefrontal cortex samples were diluted with 
water to achieve working mix of 20 μl. To the working mix, 35 μl of DNA protect 
buffer and 85 μl of bisulphite solution was added and vortex to achieve the 
reaction, indicated when the solution turned blue. The eppendorf’s were placed 
in the eppendorf mastercycler and programmed with the following temperatures, 
denaturation 95 o C - 5 minutes, incubation 60 o C - 10 minutes, denaturation 95 o 
C - 5 minutes and incubation 60 o C – 10 minutes and hold at 18 o C. When the PCR 
was completed, 310 μl of BL buffer was added, vortex and centrifuged briefly. A 
volume of 250 μl of ethanol was added to each eppendorf vortexed for 15 
seconds and centrifuged. New collection tubes were placed on each spin column 
and centrifuged for a further minute to clear any residue left. To each spin 
column, 500 μl of wash buffer was added and placed in the centrifuge for 1 
minute at 15000 – x g. Desulphonation reaction buffer was added to each column 
and incubate at room temperature for 15 minutes. After the incubation period 
the samples were centrifuged at 15000x g for 1 minute and flow through 
discarded. 500 μl of wash buffer was added to each of the columns and placed in 
the centrifuge and spun at 15000x g for 1 minute. The previous wash step was 
repeated for a further cycle and centrifuged at 15,000 x g for 1 minute to remove 
any residual. The spin columns were placed into a sterile 1.5ml micro centrifuge 
tube and 15 μl of elution buffer was added and incubated for 1 minute, and 
centrifuge at 15,000 for another minute. An additional 15 μl of elution buffer was 
added and centrifuged for 30 seconds at 15,000 x g with the flow through 
collected as the bisulphite converted DNA. 
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3.5 Designing of IL-6 primers 
The genomic browser (https://genome-euro.ucsc.edu/index.html) which is 
publicly available was used to search for the gene of interest (IL-6) with a specific 
region surrounding the SNP found in the promoter region at -174. The IL-6 
sequence was imported into the primer design software (Pyromark assay design). 
A graphic view of the assay was shown and with a number of different sets of 
forward, reverse and sequencing primers with scores out of 100. 
 
Table 3 - Primer information for two sets of IL-6 primers. 
 Primer set 1 Primer set 2 
Forward primer AGAAAAAAAGAAAGTAAAGGAA
GAGTG 
AAAAAGAAAGTAAAGGAAGAGTGG 
Biotin labelled 
Reverse primer CCTCAAACATCTCCAATCCTATAT
TTAT 
Biotin labelled 
CCTCAAACATCTCCAATCCTATATTTA 
 
Sequencing 
primer 
AAGGAAGAGTGGTTT AAACCTTATTAAAATTATACAATAT 
Sequencing to 
analysis 
TGTTTTTTAGYGTTAGTTTTAATG
AYGATTTAAGTTGTATTTTTTTTTT
TAGTTGTGTTTTGTTATGTTAAAG
GAYGTTA TATTGTATAA 
TTTTAATAAG GTTTTTAATT 
AGTTTTATTY GTTTTGGTTT 
TATTTTTATT TTTTAA 
AACRTCCTTT AACATAACAA 
AACACAACTA AAAAAAAAAA T 
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3.6 Polymerase chain reaction (PCR) 
Amplification of DNA through PCR using the eppendorf mastercycler. In a PCR 
cabinet, the master mix was prepared on ice as followed in table 4 to avoid 
contamination. The template DNA was added outside the PCR cabinet to also 
avoid DNA contamination of the cabinet. A period of optimisation was conducted 
and 2 μl of template DNA was determined to be the ideal amount to add to 
primer set 1 and 3 μl for primer set 2. 
 
Table 4 - Reagents and volumes for PCR master mix for 1x reaction with a final volume of 25 μl 
 
 
After a period of optimisation, the PCR conditions that were deemed suitable for 
the primers are initial denaturation at 95 o C for 1 minute, denaturation at 95 o C 
for 15s, annealing at 52.6 o C for 15s and extension 72 o C for 10s. Denaturation to 
extension was repeated for 49 cycles and was held at 4 o C. The PCR products 
were stored at -20 o C until samples were used for analysis. 
 
 
 
 
 
 
PCR reagents Final concentration - 1x reaction 
Forward primer 0.5 μl 
Reverse primer 0.5 μl 
MyTaqHS 12.5 μl 
Nuclease free H20 (NF-H20) 6.0 μl 
Coral dye 10 x 2.0 μl 
Template DNA 2.0 μl primer set 1 
3.0 μl primer set 2 
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3.7 Bisulphite pyrosequencing 
DNA extracted from the prefrontal cortex was bisulphite converted and prepared 
for pyrosequencing. During the set-up period, streptavidin beads were combined 
with the PCR product and other reagents as followed in the protocol to select out 
the biotin labeled product. The DNA was denatured to produce single stranded 
molecules for the sequencing. The heat block was set to 85 oC with the Q24 plate 
holder placed on top. The cartridge was cleaned with ddH2O and checked to 
ensure that all the channels were clear from blockage. On the workstation, the 
trays were filled with wash buffer, ddH20, 70% ethanol and denaturation solution. 
The pump was switched on and cleaned using ddH20 in the workstation. The 
sepharose performance beads (GE Healthcare bioscience) were inverted to mix 
the solution to avoid damage of the beads via vortexing. Sepharose beads, binding 
buffer and PCR grade water was added to an eppendorf and mix gently in the 
volume of 1/40/14 μL. A 96 well plate was cut up to make a 24 well plate and in 
each well 55 μL of master mix was pipetted and 25 μL of amplified PCR samples. 
The PCR plate was sealed with a PCR cover film and plate was placed on the 
shaker (TS-100 thermo-shaker BioSan) for 10 minutes at 1400 rpm. The sequence 
primer is diluted to 0.3 μM in an eppendorf and vortexed. In the PyroMark Q24 
sequencing plate, 25 μL of diluted sequencing primer was added to each well and 
placed on the workstation. The PCR plate was taken off the shaker and place onto 
the workstation with the lid removed carefully. The vacuum was turned on and 
the samples were processed in the following solution. IL-6 PCR samples for 15 
seconds, 70 % ethanol for 5 seconds, denaturation buffer for 5 seconds and finally 
wash buffer for 10 seconds. The vacuum was then inverted 90o for 5 seconds to 
clear the tubes of any remaining liquid. The vacuum was switched off and placed 
in the Q24 plate and was shaken from side to side for 10 second to dislodge the 
beads. The Q24 plate was transferred onto the heat block (DB-2D, Dri-Block®, 
Techne) left for 2 minutes at 85o C. The PyroMark nucleotides were loaded into 
the PyroMark cartridge with volumes determined by the PyroMark Advanced 
software. Once the run was completed then analysis of methylation levels was 
determined using the PyroMark Q24 analysis feature. When looking at the results 
generated from pyrosequencing they are often presented as a pyrogram as seen 
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in figure 16. A pyrogram reports the signal intensity as shown on the y-axis when a 
base has been added on the x-axis.  
 
3.8 Gel electrophoresis 
An agarose gel of 2% was used in gel electrophoresis. To make the 2% agarose gel, 
1 g of agarose powder and 50 mls of 1X TBE (Tris, Boric acid and EDTA) buffer is 
heated at full power in a microwave for 1 minute, once cooled 2.5 μl Midori 
Green Advance DNA Stain (NIPPON Genetics Europe) was added (0.5 μl/10mls). 
The gel was poured into a cast and a comb placed to create the wells and allowed 
to set for around 20/30 minutes. Amplified samples were then prepared with 
loading dye with the following volumes. Total volume added to each well was 10 
μl so 10/5 = 2 μl of loading dye to 8 μl of PCR DNA sample. The gel was placed in 
the biorad tank with 1X TBE buffer and samples were loaded on to the gel. For 
sizing of the bands, a 50 bp ladder (Bioline) was ran alongside the DNA on the gel. 
The tank lid was placed on the tank and attached to the biorad power pack with 
the voltage set to 90 volts for 70 minutes. The gel was viewed using the licor 
imaging system and processed on image studio v2.0. 
 
3.9 Genotyping 
Kompetitive allele specific PCR assay (KASP) was performed to determine 
individual genotypes for rs1800795 polymorphism in n=67 prefrontal cortex brain 
samples. With the probe labelled to detect the alleles 1 and 2 which are labelled 
FAM and HEX. The sequence is detected through the changes in fluorescence. A 
96 well plate was set up for allelic discrimination with diluted DNA extracted from 
the prefrontal cortex and reaction master mix with three negative controls and 
three positive controls to aid in analysis. First port of call was to dilute the 
extracted DNA with an overall concentration of 5 ng/μL in 40 μl final volume with 
NF-H20 to dilute the DNA. The KASP master mix was created using 5 μl of KASP 
master mix solution (KASPTM, LGC), with 3 μl of NF-H20 and 0.14 μl of rs1800795 
primer. In the 96 well skirted plate 8 μl of the master mix and 2μl diluted DNA was 
allocated to each well taking care to insure template DNA is placed in the correct 
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well. The plate was covered with a slip and spun to clear any air bubbles that had 
formed. The AB step one plus real time thermocycler was set up with specific 
temperatures seen in table 5. The cycle program for this assay included a 
touchdown step. 
 
Table 5 - KASP assay thermal cycle conditions with touchdown 
 
Once the first run had been completed, it was decided that a recycle run was 
needed to migrate the points of interest further to the clusters. The recycle 
program steps are indicated in table 6 below. 
 
Table 6 - Recycling conditions for allele discrimination using KASP assay 
 
 
 
 
 
 
Once the recycle was completed then the samples were analysed on the 
Stratagene Mx3000P qPCR system (Agilent) using the Mypro analysis software. 
Data was exported into Excel and a scatter graph plotted was used to determine 
the migration and the genotypes of rs1800795 as seen in figure 4. 
Protocol stage Temperature Duration Cycles 
Step 1 - Hot start Taq 
activation 
94 o C 15 
minutes 
1 
Step 2 
Touchdown 
94 o C 20 s 10 
68 o C - 0.6 o C decrease to 
achieve final of 62 o C 
60 s 
Step 3 - Amplification 94 o C 20 s 26 
62 o C 60 s 
Step 4 - Read 30 o C 60 s 1 
Temperatures Duration Number of cycles 
94 o C 20 seconds 3 cycles 
57 o C 60 seconds 
30 o C 60 seconds 1 cycle 
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3.10 Enzyme – Linked immunosorbent assay (ELISA) 
The brain tissues were lysed with RIPA buffer (Sigma – Aldrich) which contained 
protease inhibitors cocktail (Sigma – Aldrich) to extract the protein. Protein 
concentration of IL-6 was determined using the Abcam high sensitivity human IL-6 
ELISA kit. The pre-frontal cortex samples had different total protein 
concentrations. After ELISA analysis, the results were normalised using BCA total 
protein results. The control and standards were prepared following a serial 
dilution in the protocol. In the 96 well plate the blanks, 1X Control solution and 
standards 2-6 were added in duplicate at 100 μl. IL-6 samples were placed in the 
appropriate wells at 100 μl and in duplicate when possible. 1X Biotinylated anti-IL-
6 was added to each well (50 μl), covered with PCR plate seals and incubated for 3 
hours at room temperature (18-25°C). The cover was removed after the 
incubation period and the liquid aspirated from each well. A volume of 300 μl of 1 
X wash buffer was added to each well and the liquid was aspirated. This wash step 
was repeated three more times. 1X Streptavidin-HRP solution was added at 100 μl 
into all wells, including the blanks and recovered with PCR plate seals and 
incubated at room temperature for 30 minutes. The wash step was repeated as 
above and then 100 μl of Chromogen TMB substrate solution was added into each 
well and incubate in the dark for 15 minutes at room temperature. Volume of 100 
μl of stop reagent was pipetted into each well and results were taken immediately 
after the stop reagent was added. The absorbance was read on the 
spectrophotometer using 450 nm as the primary wavelength and 620 nm as the 
reference wavelength. Three data points were excluded during this process as 
they fell outside the levels of the kit. 
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3.11 Real Time polymerase chain reaction (RT-PCR) 
Messenger RNA (mRNA) was converted into Complementary DNA (cDNA) using 
the Tetro cDNA synthesis kit (Bioline, UK) at 500ng of total RNA. This was then 
diluted 1:10 which equate to 2.5ng/μl cDNA. Primers were predesigned using the 
NCBI primer-BLAST software. The master mix consisted of 10 μl of 2x QuantiNova 
Syber green PCR master mix (quigen), 0.8 μl of forward primer, 0.8 μl of reverse 
primer (table 6 primers for RT-PCR), 6.4 μl RN – H20 and 2 μl template cDNA with 
a total volume of 20 μl. 
 
Table 7 - RT-PCR primer information. Forward and reverse primer gene of interest IL-6, 2 
housekeeping gene include β actin and GAPDH. 
 
Using a 96 well PCR plate, 18 μl of master mix was pipetted into each well. Then 2 
μl of cDNA was added with two negative controls and some samples were 
duplicated. The PCR plate was covered with a clear film and spun with a 
centrifuged to mix the solution and clear any air bubbles. The biorad RT-PCR 
machine was set up with the following thermal cycle condition. Denaturation 95 o 
C for 2 minutes, denaturation 95 o C for 5 seconds, annealing at 60 o C for 5 
seconds (read stage) and extension 72 o C for 10 seconds and this was repeated 
for 39 cycles. A melt curve analysis was added with the following setting 65 o C for 
5 seconds with increments of 0.5 o C with a plate read and 95 o C for 5 seconds. 
 
 
 
 Forward primer Reverse primer 
IL-6 Gene of interest 5′ - 
GGTACATCCTCGACGGCATCT- 3′ 
5′ - GTGCCTCTTTGCTGCTTTCAC- 
3′ 
β actin Housekeeping gene 5’- ATCCTCACCCTGAAGTACC - 3’ 5’ - ATAGCAACGTACATGGCTGG 
- 3’ 
GAPDH Housekeeping 
gene 
5’ CCGCATCTTCCTTTTGCGTCG – 
3’ 
5’ - TGGAATCGCCATGGGTGGA - 
3’ 
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Using this equation, results were normalised for IL-6 gene expression against 2 
housekeeping genes β actin and GAPDH. These particular genes are important as 
they act as the internal controls. Primer efficiency was assumed to be 100%. 
𝑅𝑒𝑙𝑎𝑡𝑖𝑣𝑒 𝑔𝑒𝑛𝑒 𝑒𝑥𝑝𝑟𝑒𝑠𝑠𝑖𝑜𝑛 =  
(𝐸GOI)
∆𝐶𝑡 𝐺𝑂𝐼
𝐺𝑒𝑜𝑀𝑒𝑎𝑛[(𝐸REF)∆𝐶𝑡 𝑅𝐸𝐹]
 
GOI = Gene of interest, 
REF = Housekeeping genes, 
E= Efficiency (2 = 100%) 
 
3.12 Immunofluorescence 
Brain samples were taken from the -80 freezer and placed on dry ice to stop the 
brain samples from thawing. The samples were mounted onto cork using Neg-50 
blue, once dried the samples were mounted on to the cryostat (LEICA CM 3050). 
The settings for the cryostat included, chamber temperature -16 o C, chuck 
temperature -18 o C and the angle of the cutting blade set to 7 o. Sections of brain 
tissue were cut and placed on the charged side of the slide. Using a PAP pen a 
circle was drawn around the section as this creates a hydrophobic barrier. The 
brain tissue samples were re hydrated with PBST (1L PBS and 500 μl Tween 20) for 
5 minutes. For 30 minutes the slides were blocked in blocking solution which 
consisted of 4% goat serum and 9.6mls of PBS with 80 μl added per a slide. This is 
to block unspecific binding of the secondary antibody. Primary antibodies used 
include anti human IL-6 anti-mouse (1/50) and Anti-NF-kB p65 (phospho S 536) 
antibody (1/100) which were pipetted into blocking solution and 80 μl added to 
each slide and incubated in the dark at 4 o C overnight. Slides were rinsed in PBS 
for 5 minutes and the secondary antibodies prepared. Alexafluro IgG 568 goat anti 
mouse was used to detect IL-6 (red) and Alexafluro 488 goat anti-rabbit IgG was 
used to detect NFĸB (green) at 1/200 for 1 hour. The slides were washed in PBS 
for 5 minutes and mounted with vector shield (h-1200 with DAPI) and covered. 
Enamel paint was used to fix the coverslips in place before viewing on the Zeiss 
fluorescence microscope with a 10 x 63 oil magnification. 
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3.13 Statistical analysis 
The SPSS statistics software package (v25.0 for Windows; SPSS, Chicago, IL) was 
used for statistical analyses and GraphPad v7. Data was tested for normality using 
the Shapiro–Wilk test. Data which is determined as normally distributed was 
presented as mean ± standard deviation (SD) or median and 25th-75th percentiles 
if not normally distributed. Table of characteristic were presented and grouped 
between genotypes to indicate any significance. IL-6 protein levels and IL-6 
expression levels was analysed using a Mann-Whitney U test. A Kruskal Wallis test 
was used to analyse the significance of IL-6 protein levels between the 3 
neuropathological hallmarks (THAL, CERAD and BRAAK). Methylation percentage 
among CpG sites were analysed using an independent T-test. Correlations 
between protein, DNA methylation and gene expression of IL-6 was determined 
with Spearman’s correlation test. Significance threshold of P=<0.05. 
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4.0 Results 
 
4.1 Optimisation of PCR for amplification of IL-6 from bisulphite converted DNA 
A period of optimisation was employed to develop the most suitable parameters 
and conditions for the IL-6 primers. To find the optimal annealing temperature a 
gradient was performed using different temperatures. These were then viewed 
on a 2% agarose gel seen below in figure 1. 
 
 
PCR gradient for optimisation purposes for primer set 1 (see table 3) on bisulphite 
converted DNA extracted from the prefrontal cortex. This revealed that the bands 
had migrated to the correct region of 265 base pair (bp). Ideally the ladder would 
have migrated more to allow a clearer picture of the migration and high molecular 
smears were detected in several wells. Annealing temperature of 58o C was 
determined the best annealing temperature. 
 
Figure 1 - Gel electrophoresis viewing PCR gradient for optimisation of IL-6 primers using 
temperatures from 52.1oC- 58.3oC. Pooled DNA was amplified using a gradient of temperatures 
and run on a 2% agarose gel with a DNA ladder and a negative control. 
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Second gradient was performed to determine if 58o C was the best annealing 
temperature by employing another gradient to include temperatures greater than 
58o C s seen below in figure 2. This was to confirm that 58 oC is the best working 
condition for set 1 IL-6 forward and reverse primers. 
 
 
 
 
 
 
 
 
 
 
 
PCR gradient for optimisation purpose for primer set 1 on bisulphite converted 
DNA revealed the bands had migrated to the correct region of 265 base pair. 
However high molecular smears were present and the annealing temperature of 
58o C was confirmed to be the optimal annealing temperature. 
 
 
 
 
 
 
 
 
Figure 2 - Gel electrophoresis viewing PCR gradient for optimisation of IL-6 primers using 
temperatures from 55.1oC- 61.3oC. Pooled DNA was amplified using a gradient of temperatures 
and run on a 2% agarose gel with a DNA ladder and a negative control. 
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First set of primers were abandoned due to the constant presence of unspecific 
binding. A period of troubleshooting was employed to determine the cause of the 
problems with primer set one. The unspecific binding was not resolved by 
increasing the temperature and altering PCR conditions. The decision was taken 
to redesign the primers around the same region, as the previous primers would 
have caused problems with pyrosequencing analysis. Primer set 2 were designed 
with a base pair length of 261 and the biotin tag was labelled on the forward 
primer meaning that sequence is now read from right to left. Optimisation to 
achieve the optimal working conditions was employed and again, a gradient was 
used with results seen in figure 3. 
 
Extracted DNA was run on a PCR at different annealing temperatures and viewed 
on a 2% agarose gel to determine the best annealing temperature for set 2 IL-6 
primer forward and reverse. The optimal annealing temperature was determined 
to be 52.6 oC which produced the brightest and clearest band. Each negative 
control produced unspecific bands around 100 base pair. 
 
 
 
 
 
Figure 3 - Gel electrophoresis viewing PCR gradient for optimisation of IL-6 primers using 
temperatures from 51oC- 59.1oC. Pooled DNA was amplified using a gradient of temperatures 
and run on a 2% agarose gel with a DNA ladder and a negative control for each sample.  
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4.2 Genotyping of IL-6 polymorphism rs1800795 
Genotyping for the IL-6 SNP rs1800795 was preformed using Kompetitive allele-
specific PCR (KASP) to determine the genotypes of the SNP in the IL-6 promoter 
region. Figure 4 shows an allele discrimination plot with homozygotes GG, 
homozygote CC and heterozygote CG genotypes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
It is possible to determine the allele frequency and input the results into the 
Hardy Weinberg Equation. Positive controls were used to help aid in determining 
the genotype and these samples were from the Myoage study, which had already 
been genotyped for the rs1800795 SNP. 
 
Allele frequency and Hardy Weinberg equation for genotyping data 
 CC genotype 24 samples 35.8% 
 CG genotype 38 samples 56.7% 
 GG genotype 5 samples 7.5% 
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Figure 4 - Allele discrimination of rs1800795 polymorphism. Black circles are 3 negative controls, red 
circles are homozygote GG genotypes, green circles are heterozygote CG, and pink circles are 
homozygote CC. Three clusters present represent the n=67 prefrontal. 
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Allele frequency 
 
 P = 86/134=0.358 
 Q= 48/134=0.642 
 
HWChi-squared test: Chi-square test for Hardy-Weinberg equilibrium (autosomal) 
p= 0.0559. Regarding the p = 0.056, this just fit within the Hardy Weinberg 
equilibrium. 
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4.3 Real time PCR of IL-6 gene expression analysis 
Detection of IL-6 expression levels was detected through RT-PCR and normalised 
against two housekeeping genes, which included β actin and GAPDH. The SYBR® 
Green reagent used during this experiment can bind to any double-stranded DNA 
product. Making it vital to check the melt curve for multiple peak formation as 
only one peak should be present. Multiple peaks would indicate that there could 
be primer dimer or nonspecific binding. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5A, B and C shows melt peak analysis of β actin, IL-6 and GAPDH. All three 
RT-PCR products produce one peak in the melt peak analysis but there is slight 
wave in the peak shown if figure 5A, B and C. This could indicate primer dimer and 
unspecific binding. 
A 
B 
C 
D 
E 
F 
Figure 5 - Melt peak analysis of (5A) βactin, (5B) IL-6 and (5C) GAPDH gene transcripts 
detected by real-time PCR. cDNA samples were amplified using RT-PCR with gene of 
interest and two housekeeping primers. Melting peak analysis was performed to confirm 
the PCR products. Amplification analysis is shown in figure 5D-F and indicates at which 
cycle the amplification starts to take place. 
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Further analysis using an electrophoresis gel to determine if the samples have 
been amplified through RT-PCR and if the deviation is indeed primer dimer or 
unspecific binding. 
 
Gel electrophoresis was used to determine that the RT-PCR analysis of IL-6, β actin 
and GAPDH had efficiently amplified and no primer dimer is present or unspecific. 
IL-6 primers were designed at 76 bp which is consistent to what was seen in the 
electrophoresis gel and β actin was design at 219 bp and GAPDH was designed at 
217 bp and this is seen in the gel electrophoresis in figure 6. 
 
 
 
 
 
 
 
 
 
Figure 6 - Gel electrophoresis viewing RT - PCR results for IL-6 – 76 bp, β actin - 219 bp and 
GAPDH – 217 bp. A few cDNA samples were run on a 2% agarose gel with a DNA ladder and a 
negative control for each gene.  
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4.4 Brain sample characteristics 
4.4.1 Table of characteristic of participants subgroup via genotype 
 
Supplementary information for n=67 prefrontal cortex samples which have been 
sub grouped by genotype of rs1800795 polymorphism. Genotype CG/GG have 
been grouped due to the small sample size for GG (n=5) and was continued to be 
grouped throughout the analysis. Some information is not present for all n=67 
prefrontal cortex samples and this is stated in the table below when different. 
Data presented as mean and standard deviation, unless stated otherwise 
a- n=23 CC genotype for BRAAK analysis 
b- Data presented as n(%) 
Table 8 - Table of characteristic of participants subgroup via genotype. Data given in mean ± 
standard deviation unless stated otherwise. Frequency for CC is n=24 and CG/GG is n=43 unless 
stated differently. 
 CC CG and GG p value 
Age at death 88.21 ±(4.72) 87.12 ± (6.73) P = 0.484 
Sex (Males/Females) 6/18 15/28  
Whole brain weight (g) 1220.29 ± 
(114.6) 
1201.14 ± 
(148.62) 
P = 0.674 
Post mortem, delay (Hours) 77.84± (45.20) 75.16± (43.37) P = 0.821 
THAL stage (amyloid deposition)b   P = 0.915 
None 6 (25 %) 11 (25.6%)  
1 3(12.5%) 8 (18.6%)  
2 2 (8.3%) 4 (9.3%)  
3 8 (33.3%) 9 (20.9%)  
4 3 (12.5%) 6 (14%)  
5 2 (8.3%) 5 (11.6%)  
CERAD score (neuritic plaques)b   P = 0.983 
None 7 (29.2%) 11 (25.6%)  
A (Sparse) 7(29.2%) 12 (27.9%)  
B (Moderate) 6 (25%) 12 (27.9%)  
C (frequent) 4 (16.7%) 8 (18.6 %)  
BRAAK stages(neurofibrillary tangles) 
ab 
  P = 0.424 
None 0 4 (9%)  
I – II 12 (52%) 17 (40)  
III – IV 8 (35 %) 17 (40 %)  
V – VI 3 (13 %) 5 (12%)  
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In the supplementary table 8, key information was analysed to determine if 
genotype has an effect. Age of death and brain weight are not significantly 
different upon genotype of rs1800795 polymorphism. Brain tissue determined to 
have the CC genotype (88.21 ± 4.72) had no significant difference in age of death 
(p=0.484) compared to those with CG/GG genotype. The whole brain weight at 
post-mortem was not significantly different (p=0.674) when compared to the 
different genotypes, CC (1220.29 ± 114.6). THAL, CERAD and BRAAK scores were 
determined to have no significance in scoring upon genotype. 
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4.4.2 IL-6 protein and AD pathology 
 
THAL, BRAAK and CERAD staging are an important classification system when 
determining AD neuropathology. These scores can be used to determine whether 
the person has AD or could be classified as a control. IL-6 protein levels were 
compared with various measures of AD neuropathology to determine if levels are 
altered at different stages among THAL, BRAAK and CERAD. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Some samples could not be classified into BRAAK staging and so these samples 
were omitted from the anaysis. Data was deemed to be not normally distributed 
which resulted in a Kruskal Wallis test being performed to look at potential 
significance in IL-6 protein levels between BRAAK staging which is scoring 
neurofibrillary tangle formation. The median and 25th-75th percentiles was 
reported in each BRAAK group for IL-6 protein levels seen in figure 7. No 
significance was found in IL-6 protein levels (P=0.504) among the different BRAAK 
staging. 
 
 
Figure 7 - Relationship of IL-6 protein levels in the different BRAAK stages. Box plot presented as 
median and 25th-75th percentiles with individual plots of each samples represented. IL-6 protein 
levels were not found to be significantly different between BRAAK staging (P=0.504) n=62.  
45 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Some samples could not be classified into Thal staging and so these samples were 
omitted from the anaysis. Thal staging data was determined to be not normally 
distributed. Kruskal Wallis test was performed to look at potential significance in 
IL-6 protein levels between THAL staging which is looking at amyloid plaque 
formation. The median and 25th-75th percentiles were reported in each THAL 
stage for IL-6 protein levels seen in figure 8. No significance was found in IL-6 
protein levels (P = 0.531) among the different THAL staging. 
 
 
 
 
 
Figure 8 - Relationship of IL-6 protein levels in the different THAL staging. Box plot 
presented as median and 25th-75th percentiles with individual plots of each samples 
represented. No significance (p = 0.531) indicated between Thal grouping and IL-6 
protein levels with a total sample size of n=63. 
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Some samples could not be classified into CERAD staging and so these samples 
were omitted from the anaysis. Data was determined to be not normally 
distributed and a Kruskal Wallis test was performed to look at potential 
significance in IL-6 protein levels between CERAD staging which is looking at 
Amyloid plaque formation. The median and 25th-75th percentiles were reported in 
each CERAD stage for IL-6 protein levels seen in figure 9. No significance was 
found in IL-6 protein levels (P = 0.718) among the different CERAD staging. 
 
 
 
 
 
 
Figure 9 - Relationship of IL-6 protein levels in the different CERAD stages. Box plot presented as 
median and 25th-75th percentiles with individual plots of each samples represented. No 
significance (P = 0.718) indicated between stages and IL-6 protein levels with a total sample 
size of n=63. 
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4.4.3 IL-6 single nucleotide polymorphism, protein levels and gene expression 
 
Levels of IL-6 total protein and relative IL-6 gene expression were compared 
between the two different genotypes of the rs1800795 polymorphism to 
determine if the levels are significantly altered upon which allele is carried. 
Indicating if particular allele alters protein and expression levels. 
 
Interleukin-6 total protein was tested for normal distribution using the Shaprio 
Wilk test. Results showed that the data is not normally distributed with a 
p=<0.000. A Mann-Whitney test was therefore performed to determine statistical 
significance. Interleukin-6 protein levels in carriers of C allele was 24.33 (20.35-
35.73) and this was not significantly higher ((309.000 (p value. 0.054)) than G 
allele carriers. There is no significance in IL-6 protein levels dependent upon 
genotype and this fits in with the latitude. 
Interleukin-6 gene expression was tested for normal distribution using the Shaprio 
Wilk test which showed a p=<0.000. A Mann-Whitney U test was preformed to 
determine any significance in expression levels depending on genotype. IL-6 gene 
expression in C allele carriers was 0.39 (0.18-2.51) and this was not significantly 
higher ((415.0 (p value .433)) than G allele carriers. 
 
Figure 10 - Gene expression of protein levels in prefrontal brain samples of CC and CG/GG 
genotype of the rs1800795 polymorphism. Box plot presented as median and 25th-75th 
percentiles with individual plots of each samples represented. A –IL-6 Protein levels in CC (n21) 
or CG/GG (n 42) genotype brain samples are not significantly different (p = 0.054) B – mRNA 
levels of IL-6 in CC (n23) and CG/GG (n 41) prefrontal cortex samples are not significantly 
different (p = 0.433).  
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A correlation determined between gene expression and IL-6 protein levels via 
genotype was employed to determine if correlation is altered. 
 
 
 
 
 
 
 
 
 
 
 
Spearman’s rho correlation was performed to determine if IL-6 protein levels have 
a correlation with IL-6 mRNA. No correlation between IL-6 mRNA expression and 
protein levels were observed in either genotype CC (n=20) p=0.980 or CG/GG 
(n=40) p=0.398. 
 
 
 
 
 
 
 
 
 
 
 
Figure 11 - Correlation of IL-6 gene expression and protein levels in the pre-frontal cortex determine by 
genotype. No significant correlation detected in CC (n=20) (p=0.980) and CG/GG (n=40) (p=0.398) of the 
rs1800795 polymorphism. 
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4.4.4 IL-6 gene expression and protein levels in the control vs early AD group 
 
Levels of IL-6 protein and relative IL-6 gene expression were compared and 
related to the control and early AD groups. Sample size was on the smaller side 
due to not every sample being determined between the control and early AD 
using the neuropathphysiology staging system. The comparison was determine if 
there is a higher expression of IL-6 in prefrontal cortex samples classed as having 
early AD. 
 
IL-6 protein levels were determined as not normally distributed and data present 
as median and 25th-75th percentiles. A Mann-Whitney test was performed to 
determine statistical significance. IL-6 total protein levels in the control group was 
23.79 (18.4 – 27.48) and this was not significantly higher (116 (p=0.905)). There is 
no significant relation between IL-6 protein levels when compared to the control 
and early AD group. 
IL-6 expression levels were determined as not normally distributed and data 
presented as median and 25th-75th percentiles. A Mann-Whitney test was 
performed to determine statistical significance. Relative IL-6 gene expression in 
the control group was 0.56 (0.21– 1.47) and this was not significantly higher 
118(p=0.968) than early AD group. There is no significance in IL-6 expression 
levels in the control and early AD groups. 
Figure 12 - Gene expression on protein levels in brain of the Control and early AD. Box plot 
presented as median and 25th-75th percentiles with individual plots of each samples 
represented. A – IL-6 Protein levels in control group (n=17) and early AD group (n=14) where 
not significant (p=0.905). B - IL-6 mRNA levels in control group (n=17) and early AD group 
(n=14) where not significant (p=0.968). Data presented as median(range) in a box and whisker 
blot with individual sample marker. 
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Further step was conducted to assess IL-6 protein levels and IL-6 mRNA 
expression levels in control and early AD groups, with further stratification into 
the two IL-6 genotypes. 
 
Table 9 - IL-6 protein and expression levels in the control and AD stratified by genotype to 
determine a significance. 
 Control P value AD P value 
IL-6 protein 
 
N=7 - CC P=0.626 N=5 - CC P=0.096 
N=10 - CG/GG N=9 - 
CG/GG 
IL-6 
expression 
 
N=7 - CC p=0.874 N=5 - CC P=0.828 
N=9 - CG/GG N=9 - 
CG/GG 
 
After further analysis of the data with the control and the early AD group being 
split by genotype, no significance was determined in IL-6 protein level and IL-6 
expression levels. Table 9 shows the analysis between the groups and the p values 
from the analysis which shows no significance.  
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4.4.5 Immunofluorescence staining 
Immunofluorescence staining was used to look at activation of IL-6 and NFκB in 
the prefrontal cortex in three control and three early AD samples. It is well known 
that during inflammation NFκB activates IL-6, which accumulates around the 
nucleus. Control and early AD samples were used to look at IL-6 accumulation and 
NFκB activation. Due to time constraints only six samples were selected for 
immunofluorescence staining. No neuronal marker was selected for staining 
leading to the cell type not being identifiable in the images. 
 
 
 
NFkB (green) A 
NFkB (green) E 
NFkB (green) I 
DAPI (Blue)   B 
DAPI (Blue) J 
DAPI (Blue) F 
IL-6 (Red)    C 
IL-6 (Red)    K 
IL-6 (Red) G 
Merge     D 
Merge            L 
Merge       H 
Figure 13 – Immunofluorescent staining results for AD human pre-frontal cortex sample stained for IL-6 
and NFκB. A-D sample 13 viewed at 10 x 63 oil magnification stained for IL-6 red, NFκB green and DAPI 
blue for nucleus. E-H sample 11 viewed at 10 x 63 oil magnification stained for IL-6 red, NFκB green and 
DAPI blue for nucleus. I-L sample 15 viewed at 10 x 63 oil magnification stained for IL-6 red, NFκB green 
and DAPI blue for nucleus. 
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Immunofluorescent staining was performed to determine IL-6 localisation in the 
prefrontal cortex of both early AD and control samples and activation of NF-κB. 
However, it is not possible to determine which cell type, as no glial cell marker 
was used to stain for glial cells such as microglia or astrocytes. This was a 
limitation of the antibodies available. Some degree of auto fluorescence was 
present in all sample, which is natural fluorescence rather than stained. IL-6 
antibody staining was strongly expressed in all samples. Indicating that IL-6 is 
expressed in early AD and control samples. Ideally, a negative control would have 
been used during the project however this was not the case. The negative control 
is important to determine the visualization from the antibody and molecule of 
interest. 
 
 
NFkB (green) A DAPI (Blue)   B IL-6 (Red)    C Merge     D 
NFkB (green)   E DAPI (Blue)   F IL-6 (Red)   G Merge  H 
NFkB (green)   I DAPI (Blue)   J IL-6 (Red) K Merge   L 
Figure 14 - Immunofluorescent staining of control human pre-frontal cortex sample stained for 
IL-6 and NFκB. A-D sample 25 viewed at 10 x 63 oil magnification stained for IL-6 red, NFκB green 
and DAPI blue for nucleus.  E-H sample 30 viewed at 10 x 63 oil magnification stained for IL-6 red, 
NFkB green and DAPI blue for nucleus. I-L sample 2 viewed at 10x63 oil magnification stained for IL-
6 red, NFkB green and DAPI blue for nucleus. 
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4.4.6 Pyrosequencing pyrogram results from human prefrontal cortex samples 
 
Figure 15 shows a schematic of the IL-6 gene and the sequence to analyse for 
pyrosequencing showing the variant in the polymorphism using primer set 2. 
 
 
In figure 15A the position of TATA, NFκB, NF-IL6, C/EBP and AP-1 was determined 
through reading the literature of another scientist researching in to the IL-6 
promoter region (Poplutz et al., 2014).  
 
 
 
 
 
 
 
Figure 15 – A – IL-6 gene promoter region schematic. B - Sequence for analysis highlighted with 
the forward reverse and sequence primer. A - Red beacon in the IL-6 promoter region schematic 
indicated 4 CpG sites. B- DNA sequence indicating forward, reverse, sequence primer and CpG 
site location in the sequence. Highlighted in yellow are the CpG sites for analysis. Highlighted in 
blue is the position of the rs1800795 polymorphism situated at -174 base pair. Depending on 
the genotype for this SNP a CpG site is added as seen in the sequence below showing the 
change at the CpG site. 
A 
B 
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Figure 16 shows two different sample results for DNA methylation depending on 
genotype. The pyrogram was analysed to ensure quality controls have passed and 
samples have been fully bisulphite converted. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The control stage passed in both programs indicating that the samples have 
passed quality control and have been fully bisulphite converted. Figure 16A 
included 4 CpG sites for DNA methylation analysis. Due to the G allele, being 
present this generates an extra CpG site, which is rs1800795 SNP. This is indicated 
at the second CpG site on the pyrograph. The signal generated from the 
pyrograph on the Y-axis has generated high signal. CpG 1 has passed with a 
methylation percentage of 16 % whereas the other three CpG site have failed 
indicated with the methylation percentage being in red. Samples were repeated in 
duplicate to show if similarity is present upon re-testing of the samples at the 
failed sites. Figure 16B shows the results from sample 9 (CC) which does not have 
the extra site at CpG 2, as the C allele does not produce the extra CpG site. Good 
signal on the Y-axis is indicated and again the first CpG site is highlight in blue 
indicating a passed result of 17% methylation whereas the other two CpG sites 
are highlighted in red indicating a failed result. Samples were repeated in 
Figure 16 - Pyrograms looking at DNA methylation in IL-6 gene depending on genotype of 
rs1800795 polymorphism. A - Pyrogram for sample 46 (CG) variant with extra CpG site noted 
at the single nucleotide polymorphism site. B - pyrograph for sample 9(CC) with 3 CpG sites 
for anaysis noted extra CpG site is not present.   
A 
B 
CpG-1 CpG-2 CpG-3 CpG-4 
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duplicate to indicate if methylation is similar. Ideally, all the samples should have 
been repeated in duplicate but due to issues that arose with the sequencer it was 
not possible to gain all the samples in repeats. Some results only had 20 μl of DNA 
rather than 25 μl, however methylation percentage did not significantly change 
with the different DNA volumes. 
 
The mean methylation percentages for all samples for each CpG site were 
presented in a bar grpah to inidicated the percentage methylation at each site. 
 
The results presented in figure 17, conclude that CpG site 3 has the highest 
overall percentage methylation of all the samples compared to the other 3 of 
which CpG site 2 in only present in the G allele carriers. 
 
 
 
 
 
 
 
Figure 17 - Mean CpG methylation of IL-6 in all brain samples at the 4 individual CpG site. CpG 2 
methylation is only presented in samples that carry CG/GG genotype (n34) in the rs1800795 
polymorphism as the G allele creates an extra CpG site in these samples. In each column, an 
individual CpG site is represented and the mean ± Standard deviation is presented. 
18.42 ± 3.58 14.02 ± 4.39 33.74 ± 5.71 30.22 ± 9.47 
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4.4.7 Methylation of IL-6 promoter CpG sites 
 
IL-6 percentage methylation in the prefrontal cortex was compared to different 
genotypes CC and CG/GG. Genotype CG/GG produces an extra CpG site at site 2 
whereas CC does not, and this could possibly have an effect on methylation levels. 
 
 
 
 
 
 
 
 
 
 
 
Data was tested for normal distribution using the Shaprio Wilk test in which the 
data was determined to be normally distributed. Through the distribution 
analysis, an independent t-test was selected for analysis to determine if genotype 
affects the levels of methylation at each CpG site. CpG site 1 percentage 
methylation in CC genotype were not significantly different (p=0.773) from CG/GG 
genotype and amounted to 18.26 ± 3.56 and 18.54 ± 3.64 respectively. CpG site 3 
percentage methylation in CC genotype group were significantly different 
(p=0.004) from CG/GG genotype and amounted to 36.37 ± 5.34 and 32 ± 5.34 
respectively. CpG site 4 percentage methylation in CC genotype group were 
significantly different (p<0.000) from CG/GG genotype and amounted to 20.35 ± 
4.42 and 36.91 ± 5.03 respectively. 
Figure 18 - Methylation percentage at 4 CpG sites of CC (n 23) and CG/GG (n 34) genotype of the 
rs1800795 polymorphism, data present as mean ± standard deviation. CpG site 1 methylation 
not significantly different between genotypes (p=0.733). CpG site 2 (SNP) was only present in 
the G allele carriers. CpG site 3 methylations significantly different between genotypes 
p=0.004) CpG site 4 methylation significantly different in genotypes (p<0.000). 
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Methylation percentage for all CpG site were tested against the control and early 
AD groups to determine if there is significant difference in methylation. 
 
 
Data was determined to be normally distributed and an independent t – test was 
used to analyse if percentage methylation at the 4 CpG sites are different 
between the control group and early AD group. CpG site 1, percentage 
methylation 19.17 ± 4.25 in the control group was not significantly different 
(p=0.586) from the AD group. CpG site 2, percentage methylation 14.69 ± 4.54 in 
the control group was not significantly different (p=0.582) from the AD group. 
CpG site 3, percentage methylation 35 ± 5.75 in the control group was not 
significantly different (P=0.692) from the AD group. CpG site 4, Percentage 
methylation 30 ± 11.87 in the control group was not significantly different 
(p=0.986) from the AD group. 
 
 
 
Figure 19 – Mean methylation levels at all CpG 4 sites in control and AD groups were analysed and 
data presented as mean ± standard deviation. CpG site 1 methylation not significantly different 
between control and early AD (p=0.586). CpG site 2methylation not significantly different between 
the control group (p=0.582) and early AD. CpG site 3 methylations was not significantly different 
between the control group (p=0.692) and early AD. CpG site 4 methylation was not significantly 
different in the control group (p=0.986). 
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4.4.8 Interaction of IL-6 protein and gene expression vs DNA methylation dependent 
upon genotype 
 
A correlation between IL-6 protein levels to each CpG site was analysed and 
stratified into genotypes (CC n=20 and CG/GG n=34) to determine if an 
association or difference occurs depending on the genotype. CpG site 2 
methylation is not analysed, as this is only present in the G allele carriers. Looking 
at figure 20 no correlation was present and further analysis took place.  
 
 
A spearman correlation analysis was used to determine the possible relationship 
between IL-6 promoter methylation and protein levels. The data was grouped into 
genotypes to determine significance between CC and CG/GG genotype of 
rs1800795 polymorphism. 
Figure 20 – Correlation of IL-6 total protein and each CpG site methylation depending on the 
genotype. A– Correlation between levels of IL-6 protein and methylation at CpG site 1 depending 
upon genotype of rs1800795 polymorphism. B – Correlation between levels of IL-6 protein and 
methylation at CpG site 3 depending upon genotype of rs1800795 polymorphism. C– Correlation 
between levels of IL-6 protein and methylation at CpG site 4 depending upon genotype of 
rs1800795 polymorphism. 
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No correlation was observed in the CC (n=20) genotype and no significances 
between IL-6 protein levels with CpG site 1 (p=0.436), CpG site 3 (p=0.681) and 4 
(p=0.383) were determined. No association was found between IL-6 protein levels 
in CpG site 1 (p=0.505), 3 (p=0.545) and 4 (p=0.294) in the CG/GG genotype group 
n=34). This shows that methylation levels are not correlated with protein levels 
upon genotype. 
 
Further analysis was conducted, and a comparison was determined between each 
CpG site and IL-6 gene expression levels stratified into genotype to determine if 
methylation levels correspond to the levels of expression. 
 
Table 10 - Spearman’s correlation analysis on IL-6 proteins levels at each individual CpG compared 
between genotypes of the rs1800795 polymorphism. 
CC correlation 
coefficient 
p value CG/GG correlation 
coefficient 
p value 
Total protein IL-6 
compared to 
CpG 1 
-.249 P=0.436 Total protein IL-
6 compared to 
CpG 1 
.127 P=0.505 
Total protein IL-6 
compared to 
CpG 3 
-.133 P=0.681 Total protein IL-
6 compared to 
CpG 3 
.115 p=0.545 
Total protein IL-6 
compared to 
CpG 4 
-.277 P=0.383 Total protein IL-
6 compared to 
CpG 4 
.198 p=0.294 
CC correlation 
coefficient 
p value CG and GG correlation 
coefficient 
p value 
IL-6 expression 
compared to 
CpG 1 
.034 p=0.870 IL-6 expression 
compared to 
CpG 1 
.099 p=0.589 
IL-6 expression 
compared to 
CpG 3 
-.049 p=0.828 IL-6 expression 
compared to 
CpG 3 
.160 p=0.382 
IL-6 expression 
compared to 
CpG 4 
.030 p=0.894 IL-6 expression 
compared to 
CpG 4 
.146 p=0.425 
Table 11 - Spearman’s correlation analysis of IL-6 gene expression at each individual CpG site 
compared between the genotypes of the rs1800795 polymorphism. 
60 
 
 
No correlation between IL-6 gene expression with CpG site 1 (p = 0.870), 3 
(p=0.828) and 4 (p=0.894) were found in the CC genotype group n =20. No 
association was found between IL-6 gene expression levels in CpG site 1 
(p=0.589), 3 (p=0.382) and 4 (p=0.425) in the CG/GG genotype group n (34). This 
shows that IL-6 gene expression is not regulated by DNA methylation and not 
affected depending on genotype carried in the rs1800795 polymorphism. Overall 
the result suggests, that protein levels and gene expression levels for the IL-6 
gene are not correlated to methylation at each of the 3 CpG sites with CpG site 2 
missing as present only in G allele carriers. 
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4.4.9 Comparison of IL-6 protein levels in the brain in relation to DNA methylation at 
all CpG sites stratified into early AD and control. 
 
Levels of IL-6 total protein were correlated to each CpG site to indicate if a 
relationship occurs and if there is any difference between the control and early 
AD group. This analysis is to indicate if levels of IL-6 protein fluctuate together 
with each CpG site in control and early AD samples to indicate any correlation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Looking at the scatter plots, the distribution of samples in the control and early 
AD group showed no correlation was present. To further enhance analysis a 
correlation test was performed to confirm the finding in the scatter plot. 
 
 
 
Figure 21 –Correlation of IL-6 protein levels at each CpG site in control and early AD group. A– 
Correlation between levels of IL-6 protein and methylation at CpG site 1 in control and early AD 
group. B – Correlation between levels of IL-6 protein and methylation at CpG site 2 in control 
and early AD group. C – Correlation between levels of IL-6 protein and methylation at CpG site 3 
in control and early AD group. D– Correlation between levels of IL-6 protein and methylation at 
CpG site 4 in control and early AD group. 
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Table 12 - Spearman’s correlation of each CpG site methylation and IL-6 protein levels in control 
and AD groups 
Control Correlation 
coefficient 
P value Early AD Correlation 
coefficient 
P value 
IL-6 total 
protein 
compared to 
CpG 1 
-.253 p=0.363 IL-6 total 
protein 
compared 
to CpG 1 
-.268 p=0.400 
IL-6 total 
protein 
compared to 
CpG 2 
-.599 p=0.117 IL-6 total 
protein 
compared 
to CpG 2 
.273 p=0.554 
IL-6 total 
protein 
compared to 
CpG 3 
-.117 p=0.679 Il-6 total 
protein 
compared 
to CpG 3 
.011 p=0.974 
IL-6 total 
protein 
compared to 
CpG 4 
-.269 p=0.333 IL-6 total 
protein 
compared 
to CpG 4 
-228 p=0.476 
 
Looking at the results from the control group there was no correlation presented 
in the individual CpG sites and total protein IL-6 levels. In the early AD group, 
there was no correlation between IL-6 total protein levels and the individual CpG 
sites. It has to be noted that the sample size for these groups are small. As not all 
samples can be grouped into control or early AD using THAL, CERAD and BRAAK 
scores. 
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5.0 Discussion 
 
This project investigates the epigenetic regulation of IL-6 within the prefrontal 
cortex of AD and control brain samples to understand how the IL-6 gene is 
regulated during cognitive decline and AD. IL-6, a cytokine with both pro- and 
anti-inflammatory properties, is seen to have a role in a number of different 
neurological conditions in which neuroinflammation is a component, such as AD. 
We found that IL-6 protein levels and IL-6 mRNA levels were not impacted by 
genotype and disease state. Interestingly, DNA Methylation was seen to be 
altered in the presence of a SNP, suggesting GxE. However, this was not 
influenced by disease state. 
 
5.1 The impact of AD neuropathology and IL-6 protein expression 
This is the first study to investigate the levels of IL-6 within the brains of 
cognitively healthy and AD. Interleukin 6 protein levels in the control and AD 
samples were collectively analysed to determine if levels are altered at the 
different stages of AD neuropathology with IL-6 levels compared to BRAAK, THAL 
and CERAD staging 
This study found that protein levels were not significantly altered at the different 
staging classification among BRAAK (p = 0.504), CERAD (p = 0.718) and THAL (p = 
0.531). Overall, the results suggest that protein levels are not significantly altered 
at the different stages in AD neuropathology classification. This analysis indicates 
that IL-6 protein expression alone does not correlate with neuropathology. 
Indicating that other mechanisms could be at work or that IL-6 in other brain 
regions might have more of a role in AD. 
IL-6 is produced by a number of different cell types in the brain which include 
neurons, microglia and astrocytes (María Erta, 2012). As IL-6 is produced by many 
different cells this could have an impact as other brain regions may have higher IL-
6 levels compared to other areas such as the prefrontal cortex which as of yet is 
presently uncertain. Further analysis to determine possible brain region and cell-
specific variations in IL-6 regulation would be important. As stated above IL-6 is 
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produced by many different cell types and levels of IL-6 may vary in different brain 
regions. Such spatial temporal analysis, that may for example reflect particular cell 
densities of microglia, could shed more light on mechanisms in which IL-6 is 
controlled and how this might further regulate subsequent neuroinflammatory 
responses. As well as this, the production of inflammatory factors in the brain 
from these cells could occur due to the response to injury, inflammation, trauma 
and neuropathological hallmarks such as amyloid plaques (Harry and Kraft, 2008). 
This is important to note as during this study, these factors could not be 
controlled for and this potentially could have an effect. Analysis through blood 
and CSF have indicated that levels of IL-6 are having an effect on traumatic brain 
injury (Woodcock and Morganti-Kossmann, 2013). IL-6 is seen to be upregulated 
in neuroinflammation when infection and injury occurs in the central nervous 
system (María Erta, 2012). Levels of IL-6 in the CSF have been seen to be 
significantly increased compared to plasma levels in people who had suffered 
traumatic brain injury (Woodcock and Morganti-Kossmann, 2013). It must be 
noted that they are looking at plasma levels whereas this study looked at 
prefrontal cortex brain tissue. However brain levels of IL-6 may be similarly 
affected. In conclusion, other factors would have affected the levels of IL-6 and 
AD neuropathology. During the analysis of the prefrontal cortex it was not known 
if any had suffered from a TBI or infection which could have in turn affected levels 
of IL-6 in relation to neuropathology. 
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5.2 – The impact of -174 polymorphism, IL-6 protein, L-6 mRNA expression levels 
and difference between control and AD. 
 
In this study, the transcriptional role of the rs1800795 polymorphism in the 
regulation of protein expression and IL-6 mRNA in prefrontal cortex brains in 
relation to cognitive decline and AD pathology was investigated.  
 
Genotyping analysis was first performed to determine the genotype of the n=67 
samples. Using the Hardy Weinberg calculation for the SNP analysis, a p value of 
0.059 was obtained. The indicates that the genotype fits into the Hardy Weinberg 
equilibrium validates that the genotypes in this study are correct. However, a p 
value of 0.059 which suggests the power of the analysis is low and a greater 
sample size would be needed to increase statistical power for a SNP genotyping 
analysis. 
 
Interesting, there was a lack of correlation between IL-6 mRNA levels and IL-6 
protein levels. This suggests that many factors may affect the pathway from DNA 
to RNA to protein. Problems can arise in the translation of mRNA to protein 
leading to proliferation and death. This is a complex process that does not always 
lead to a direct correlation between protein and IL-6 gene expression levels. 
However, it appears that the SNP has no direct impact in IL-6 protein levels and IL-
6 gene expression levels in control and AD pre-frontal cortex samples collectively. 
 
IL-6 protein levels were analysed between genotypes of the rs1800795 
polymorphism (CC and CG/GG) to see if genotype affect IL-6 levels in the 
prefrontal cortex. The results indicated that IL-6 protein levels boarder on 
significance (p=0.054) when classed by genotype. This suggests levels of IL-6 in 
brain tissues may potentially be regulated by the IL-6 polymorphism rs1800795. 
Further analysis would be needed with a greater sample size to determine if the 
SNP indeed influences the protein levels in the brain on replicate studies to 
understand possible mechanism. Albani et al. (2009) found that there was a 
correlation between levels of IL-6 plasma and the rs1800795 genotype in aging. 
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They observed that there are higher circulating levels of IL-6 in the GG genotype 
compared to the CC genotype. It must be noted that this study was done using 
peripheral blood rather than human brain tissue. This suggests that protein levels 
could be dependent on tissue and sample type. Licastro et al. (2003) found that 
homozygous for the rs1800795 genotype CC had an elevated risk of developing 
AD. They found that allele variance of the IL-6 gene does influence brain and 
blood levels of the IL-6 cytokine in AD patients. Overall, there are still conflicting 
results and further analysis with a greater sample size would be beneficial, to 
drawing significant conclusions. Levels of IL-6 mRNA were compared to the 
rs1800795 polymorphism to determine if this particular SNP alters expression 
levels of IL-6 found in the prefrontal cortex. Statistical analysis of the results 
indicated that IL-6 expression levels were not significantly altered between the 
genotypes of the IL-6 polymorphism (p=0.433). This suggests that the G allele 
does not confer increased transcription in these brain samples of AD and control 
together. 
 
Levels of IL-6 protein were further analysed to determine if they are altered 
between the control group and AD group. The prefrontal cortex samples were 
classified using the BRAAK, THAL and CERAD staging. Statistical analysis of the 
results found no significance (p=0.905) between the control or early AD groups 
and the levels of IL-6 protein expressed in the brain tissue. This result suggests 
that IL-6 protein levels in the prefrontal cortex of the control and early AD groups 
are not affected by disease state. Further analysis was conducted on RNA 
expression levels between AD and Control which found no significance in 
expression levels between the two groups (p=0.097). Indicating that IL-6 
expression levels are no different in the control and AD groups. Further analysis 
was conducted by further stratifying the samples into the rs1800795 genotypes. 
No significance was found in the results. The results suggest that levels of IL-6 
protein are not altered between genotype and disease state. Studies have been 
relatively inconsistent when studying IL-6 polymorphism and interaction to AD 
risk. One report found that individuals with the CC genotype of rs1800795 have a 
significantly greater risk of developing Alzheimer’s disease (Chen et al., 2016), 
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whereas there have been several studies conducted by different countries (Italy, 
Japan and Spain) which have showed a progressive association of the IL-6 G allele 
in the AD (Mateo et al. 2006, Pola et al. 2002, Shibata et al. 2002). In contrast 
Depboylu et al. (2004) concluded that IL-6 (-174) polymorphism does not 
influence the risk of developing AD in their cohort of German participants. One 
limitation to the research is the quality of the mRNA in the post-mortem brains 
and these could potentially effect the analysis and the quality of the results.  
 
IL-6 was seen to be present in the immunofluorescent stained samples of both 
the control and early AD groups. However due to no neuronal marker being used 
it was impossible to determine which cells IL-6 accumulated around. The results 
suggest that IL-6 is present in both healthy controls and AD samples as well as 
NFkB was activated around the nucleus in both control and AD samples. However, 
these results cannot be analysed or considered due to sample size and brain 
tissues not being stained for a neural marker. It can be concluded that IL-6 does 
accumulate in the brain, however it was not possible to determine if levels were 
significantly different between the control and AD group. NFkB plays an important 
role in inflammation as this transcription factor can cause transcription to occur in 
proinflammatory gene for example IL-6 (Tak and Firestein, 2001). The above result 
is suggesting the possibility that inflammation indeed could be occurring in not 
only AD brains but control brains too.  
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5.3 IL-6 methylation levels 
Epigenetic regulation is an important factor in regulating neuroinflammatory 
systems and has been linked to the pathogenesis of neurodegenerative diseases. 
One type of epigenetic marker, DNA Methylation, is increasingly implicated in 
various diseases (Ryan et al., 2017) with strong links between neuroinflammation 
and epigenetics (Garden, 2013) as well as studies conducted on altering DNA 
methylation in AD. 
 
Methylation percentages were determined for each CpG site and compared 
between the rs1800795 (-174 SNP) polymorphisms to assess if the genotype 
alters IL-6 methylation levels. The IL-6 methylation levels were not deemed 
significant at CpG site 1 between the genotypes (p =0.733). However, CpG site 3 
and 4 were deemed significantly different between the two genotype groups 
(CpG 3 – p=0.004 and CpG 4 -p=<0.000). These results indicate that, within the G 
allele, methylation levels are increased in neighbouring CpG sites compared to the 
C allele. Indicating that the rs1800795 SNP has an effect upon methylation levels 
in the IL-6 promoter region among the control and early AD prefrontal cortex 
samples collectively. This is important as this suggests that genotype influences 
methylation which could in turn affect transcription of the IL-6 gene. It is still not 
clear how methylation at just one CpG site can affect the promoter region. One 
possible suggestion could be when one CpG site is contained within a 
transcriptional binding site it could in turn affect the binding. Studies have found 
that individuals with AD tend to have higher levels of DNA methylation compared 
to the cognitively normal (Yokoyama et al., 2017). With this in mind, the results 
would suggests that the C allele may have a protective element through 
decreasing methylation levels compared to the G allele present at the SNP, which 
shows an increased risk through increasing methylation levels. This, in turn, could 
increase the risk of developing AD. It has been suggested, in previous studies, DNA 
methylation differences at single CpG sites altered IL-6 expression in Rheumatoid 
arthritis patient monocytes. However, this association was not deemed to be 
linked to the rs1800795 genotype (Noss et al., 2015). Methylation levels were 
compared solely to the control and early AD groups and no significance was 
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found. This suggests that methylation levels alone are not altered in the control 
and early AD groups at each of the CpG sites.  
 
IL-6 protein levels were correlated to CpG site 1, 3 and 4 (CpG site 2 SNP was 
omitted as only present in the CG/GG genotype) to determine if IL-6 levels are 
correlated with IL-6 methylation levels depending on genotype present. No 
correlation was determined in the CC genotype and no significance between IL-6 
protein and methylation levels at each CpG site. The CG/GG was determined to 
have no correlation or significance between IL-6 protein and methylation levels at 
each CpG site. These results suggest that the SNP does not have a impact on the 
correlation between levels of IL-6 and methylation, suggesting that other factors 
could play a role in DNA methylation, e.g. various environmental factors 
underlying gene by environment (GxE). 
 
IL-6 gene expression levels were compared to each individual CpG site and split 
into genotype of the rs1800795 SNP. Results indicated no correlation in IL-6 
expression and methylation levels at each CpG site upon genotype. This suggests 
that the SNP, which produces an extra CpG site in the G allele carriers, does not 
have a role in altering IL-6 expression and methylation at each CpG site located in 
the IL-6 promoter region. Interestingly, although CpG DNA methylation is 
generally associated with low gene expression, Noss et al. (2015) found poor 
correlation between IL-6 expression and promoter CpG methylation. 
 
IL-6 protein levels and gene expression levels were correlated to methylation 
percentage at each of the CpG sites. Looking at the control group there was no 
correlation and no significance determined between total protein IL-6 levels and 
the individual CpG sites, which was noted in the early AD group too. Although a 
relatively low sample size this result suggests that DNA methylation does not 
impact on expression levels of IL-6 and the protein levels in the prefrontal cortex. 
This implies that other factors could influence DNA methylation and IL-6 levels 
may well be present in different tissue type. Decreased methylation is generally 
associated with transcriptional activation. Epigenetic mechanism has been shown 
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to have a role in the regulation of IL-6, allowing regulation independently of 
genetic sequence. For example, methylation is an important factor in the control 
of IL-6 and the production of this cytokine may lead to the production being 
altered as seen in Rheumatoid arthritis (Nile et al., 2008). Furthermore, a twin 
study looking at DNA methylation, one with AD and other cognitively normal 
found that levels of methylation were decreased in the prefrontal cortex of the 
AD sufferers (Mastroeni et al., 2011). In contrast to this a similar study using the 
same methods found that levels were increased in DNA methylation. An example 
of this would be a study found that in the middle gyrus levels of methylation had 
been significantly increased (Coppieters et al., 2014). 
 
In summary, IL-6 mRNA and IL-6 protein levels are not directly impacted by the 
rs1800795 polymorphism in the prefrontal cortex samples indicating that other 
factors could have an impact such chromatin modifications. Methylation levels at 
CpG sites 3 and 4 were significantly dependent upon genotype. However, 
when related to IL-6 protein and mRNA expression levels in the brain, no 
significance was found. This suggests that DNA methylation is not direly regulating 
brain IL-6 expression and protein levels depend on the genotypes. However, DNA 
methylation may play a role through gene environment interaction GxE. This is 
defined as when two different genotypes respond to environment variation in 
different ways. The environment interaction could include exposure to physical, 
chemical, biological factors and life events (Tanaka et al., 2014). This leads to the 
question as to whether such environment interactions could have a potential 
effect on the transcriptional and expression of IL-6 in this study in response to 
disease for example. Having different genotypes could influence the response to 
environmental variation however, this GxE concept still remains largely unclear 
(Fave et al., 2018).There have been a few studies relating GxE and AD. For 
example, a study was conducted on AD patients who carry the ApoE4 genotype. 
They were found to have greater cognitive decline when linked to increased levels 
of cholesterol compared to normal levels when grouped by the present or absents 
of the ApoE 4 genotype (Evans et al., 2004). Sporadic cases of AD can be linked to 
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GxE and, similarly environmental exposure during early stages of life has been 
seen to impact on complex psychiatric disorders (Chouliaras et al., 2010b)      
 
To summarise, the research has shown that IL-6 is present in control and AD 
brains and the SNP has an impact on methylation levels between genotype at 
different CpG sites however direct linear correlations between methylation, 
protein and expression levels did not exist within this study. 
6.0 Limitation 
In this particular study using prefrontal cortex samples from the University of 
Manchester Age and Cognitive performance Research Cohort (ACPRC) it was 
possible to research the epigenetic regulation of IL-6 in age-related cognitive 
decline and AD. This study is unique and novel as it included human brain tissue 
from a well characterised cohort as opposed to previous analysis focused on CSF 
and blood. However, some limitation exist due to the nature of the research and 
the tissue type being used, in this case the human brain. 
A correlation analysis was conducted on IL-6 expression levels and RIN values. RIN 
values were on the lower side (3.69 ± 1.38) indicating that the quality of the RNA 
is low which is often the case in post-mortem brains. Acceptable RIN values would 
be over 6. This in turn could affect the results when looking at gene expression. 
Ideally, better quality RNA would be needed to improve the validity of the results 
for RNA expression. 
 
The sample size in this study, looking at the effect IL-6 promoter region SNP, was 
not adequate with the Hardy Weinberg giving a p value of 0.054, suggesting that a 
greater sample size is needed for a more robust statistical analysis. When 
statistical analyses took place on IL-6 protein and expression levels in the control 
and AD groups stratified by genotype it has to be noted that sample size was 
further decreased. This was due to some samples not being classified into either 
being control or early AD. A greater sample size would be better for a more robust 
statistical analysis. 
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A limitation of immunofluorescence staining was the brain sample tissue obtained 
from the brain bank. When sectioning the tissue for IHC the tissues were not 
cutting smoothly. The temperature in the cryostat was altered +/- several degrees 
with the starting chamber temperature of -16 to try and improve the sectioning of 
the samples. It also appeared there was vacuolisation in the brain tissue. As the 
tissues have come from the brain bank the way the tissue has been frozen could 
have caused damage. Ideally if more analysis was conducted wax imbedded tissue 
would be more suitable as the whole brain is dipped in wax and there is less 
chance of damage. 
 
7.0 Further research 
This study has shown that IL-6 is indeed present in the brain and that the SNP has 
an impact in DNA methylation in the brain. However, linear correlations were not 
observed between methylation, protein and expression. Further research needs 
to be conducted on gene regulation in cognitive decline and Alzheimer disease 
using human brain samples. Targeted approaches such as mapping of methylation 
are important to allow investigation genetic-epigenetic-protein interactions. 
However, geneome wide analyses could be important to identify specific immune 
pathways that perhaps IL-6 might be part of. It is also unclear whether IL-6 might 
be a cause or consequence of the neuroinflammation in respect to both its pro 
and anti-inflammatory activities. Further investigation as to these roles and which 
cells are secreting this cytokine could allow researchers to better determine the 
pathways by which IL-6 is regulated. Data on activity of microglia, as a marker for 
neuroinflammation, could be useful to further link this correlates with IL-6 levels. 
Further research of the polymorphism would be needed with a greater sample 
size for polymorphism analysis. Though this cohort is well studied with 
longitudinal and neuropathological data, larger numbers are generally needed for 
a high-powered association study. A further Genome Wide Association Study 
(GWAS) analysis would further allow to investigate other SNPs at the IL-6 locus 
and perform haplotype mapping. GWAS data might also allow the development of 
polygeneic risk scores for neuroinflammation that IL-6 might form part off. 
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DNA methylation is an important epigenetic regulator and was measured at the 
IL-6 promoter. However, other regions of the IL-6 locus might also be important, 
such as enhancers of which IL-6 has several and more distal promoter regions or 
the coding region itself. Though targeted DNA methylation by bisulphite 
pyrosequencing is highly specific and sensitive, geneome wide approaches would 
allow more coverage of the locus. Another point is whether other epigenetic 
markers such as various chromatin markers might also have a role in the 
regulation of IL-6. Histone modification is seen in aging with a decrease in 
acetylation and increase in phosphorylation Comparing IL-6 expression, protein 
levels and DNA methylation levels to other parts of the brain, for example the 
hippocampus would allow comparison to assess to compare if levels are altered in 
different parts of the brain in relation to AD vs Control. 
8.0 Conclusion 
 
By using human brain samples from the prefrontal cortex, we were able to 
provide an insight into the regulation of the IL-6 gene during cognitive decline and 
AD. From this project it was determined that IL-6 does play a role in inflammation 
with specifics to neuroinflammation. However, it was not determined if the SNP 
(rs1800795) in the promoter region impacted the regulation of IL-6 cytokine and 
expression levels. 
 
This study found that DNA methylation at the IL-6 promoter did not directly 
associate with IL-6 expression levels within the brain of individuals with AD. 
However, the G/C SNP rs1800795 did impact DNA methylation levels. There was 
obviously no methylation at CpG Site 2 in the CC homozygotes in which this CpG 
site is no longer present. Methylation at CpG site 3 was significantly decreased in 
G allele carriers compared to CC homozygotes (p=0.004), whereas at CpG Site 4 
the G allele carriers showed significantly increased DNA methylation compared to 
CC homozygotes (p>0.000) (figure 18). 
 
This implies that other factors could have an impact such a gene by environment 
interaction. These results suggest that other factors could influence the 
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epigenetic regulation of IL-6 and in a multifactorial mechanism. Biological 
pathways and gene transcriptional activity can be changed through epigenetics. 
Factors that could potentially affect this include the environment such as toxins 
and hazardous exposure which could alter gene expression. Gene environment 
interaction is an influence that could affect epigenetic regulation through SNP 
interaction. 
 
Observations during this project indicated that IL-6 is indeed present in both 
control and early AD but multiple factors could be involved in the regulation of IL-
6 during cognitive decline and early AD. Further analysis would need to be 
conducted with a greater samples size when determining the SNP significance in 
relation to expression and protein levels and the impact on AD. 
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10.0 Appendix 
10.1 table of chemical, reagents and kits 
96 well plate Starline 
Q24 sequence plate Quigen 
0.2ml PCR tubes Starline 
Pipette tips 10ul,20ul,200ul,1000ul  
PCR plate cover slips  
Nuclease free water  
PCR grade water  
Isolate 2 genomic DNA extraction kit Bio line 
EpiTec fast Bisulphite kit Quigen 
ELISA anti human IL-6 Abcam 
Pyromark q24 regents Quigen 
Agarose powder  
Tris base  
EDTA  
Boric acid  
Syber green dye Quigen 
DNA ladder 100bp Bioline 
MyTaqHS Bioline 
Coral Dye 10x  
70% ethanol  
Denaturing buffer  
Washing buffer  
IL-6 forward primer Invergion 
IL-6 reverse primer Invergion 
IL-6 sequence primer Invergion 
RT PCR IL-6 Forward primer Invergion 
RT PCR IL-6 Reverse primer Invergion 
RT PCR B actin Forward primer Invergion 
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RT PCR B actin Reverse primer Invergion 
KASP master mix  
Rs1800795 primer  
IL-6 anti human anti mouse R&D 
Anti-NF-kB p65 (phospho S536) 
antibody 
Abcam (ab28856) 
Vector shield DAPI  
Alexfluro IgG 568 goat anti mouse red  
Alexfluro IgG 488 goat anti rabbit green  
StepOne plus  
Fluorescence microscope  
Biorad RT PCR machine Biorad 
Eppendorf master cycler  
Pyro mark sequencer Quigen 
Biorad power pack and tank Biorad 
  
 
 
 
 
 
 
 
